April 15th 2025
In a phase 3 study, GSK’s gepotidacin demonstrated 92% efficacy against the sexually transmitted infection.
Why is Multidrug-Resistant Pseudomonas aeruginosa a Priority Pathogen?
June 13th 2017Jason Pogue, PharmD, BCPS-ID, Clinical Pharmacist, Infectious Diseases, Sinai-Grace Hospital, explains why Pseudomonas aeruginosa is one of the World Health Organization’s critical priority pathogens for new research and development priorities.
Watch